checkAd

Gilead’s Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS

Gilead Sciences, Inc. (Nasdaq: GILD) will present additional data from the Phase 3 ASCENT study of Trodelvy (sacituzumab govitecan-hziy) during the upcoming San Antonio Breast Cancer Symposium (SABCS) being held from December 7-10. These data reinforce the benefits of Trodelvy and the importance of Gilead’s transformative science in cancers with high unmet need. In the United States, Trodelvy is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.

“Our data at SABCS add to the growing body of evidence supporting the use of Trodelvy for people with metastatic TNBC,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. “We continue to advance the treatment of TNBC and are actively exploring the potential of Trodelvy across the breast cancer landscape.”

Handeln Sie Ihre Einschätzung zu Gilead Sciences Inc!
Long
Basispreis 61,76€
Hebel 9,29
Ask 0,65
Short
Basispreis 74,88€
Hebel 8,65
Ask 0,62

Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

Highlights at the meeting include an ASCENT analysis examining outcomes for Black patients with metastatic TNBC who were treated with Trodelvy compared to those receiving physician’s choice of chemotherapy. Additional ASCENT analyses will explore health-related quality of life (HRQoL) measures by clinical response and post-progression treatment and survival of patients who experienced continued disease progression.

Accepted abstracts are as follows:

  • Assessment of Sacituzumab Govitecan in Black Patients from the Phase 3 ASCENT Study in Metastatic Triple-Negative Breast Cancer (Poster #P5-16-07)
  • Post-Progression Therapy Outcomes in Patients from the Phase 3 ASCENT Study of Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer (Poster # P5-16-15)
  • Assessment of Health-Related Quality of Life by Clinical Response from the Phase 3 ASCENT Study in Metastatic Triple-Negative Breast Cancer (Poster #P5-16-01)

The presentations will be made available in-person and on-demand as part of Poster Session 5 beginning Friday, December 10 at 7:00 a.m. CT.

For more information, including a complete list of abstract titles at the meeting, please visit: https://www.sabcs.org/Program/Schedule-at-a-Glance.

The Trodelvy U.S. Prescribing Information has a BOXED WARNING for severe or life-threatening neutropenia and severe diarrhea; see below for Important Safety Information.

About Triple-Negative Breast Cancer (TNBC)

TNBC is the most aggressive type of breast cancer and accounts for approximately 15% of all breast cancers. TNBC is diagnosed more frequently in younger and premenopausal women and is more prevalent in Black and Hispanic women. TNBC cells do not have estrogen and progesterone receptors and have limited human epidermal growth factor receptor 2 (HER2). Due to the nature of TNBC, effective treatment options are extremely limited compared with other breast cancer types. TNBC has a higher chance of recurrence and metastases than other breast cancer types. The average time to metastatic recurrence for TNBC is approximately 2.6 years compared with 5 years for other breast cancers, and the relative five-year survival rate is much lower. Among women with metastatic TNBC, the five-year survival rate is 12%, compared with 28% for those with other types of metastatic breast cancer.

Seite 1 von 6


Wertpapier



0 Kommentare
Nachrichtenquelle: Business Wire (engl.)
29.11.2021, 14:30  |  102   |   |   

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Gilead’s Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS Gilead Sciences, Inc. (Nasdaq: GILD) will present additional data from the Phase 3 ASCENT study of Trodelvy (sacituzumab govitecan-hziy) during the upcoming San Antonio Breast Cancer Symposium (SABCS) being held from December 7-10. These data …

Nachrichten des Autors

Titel
Titel
Titel
Titel